Follicular lymphoma: Emerging therapeutic strategies

Vaishalee P. Kenkre, Brad S. Kahl

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden. Decision-making to treat in the frontline is based on histology, disease burden and patient symptoms. The general approach should be a combination of rituximab and chemotherapy, traditionally using alkylating agents, with or without an anthracycline, with more recent evidence for the alternative of bendamustine. Relapsed/refractory follicular lymphoma carries similar variability in presentation. Therapeutic options include the same regimens traditionally used for first-line therapy; however, they also include agents, such as bendamustine, bortezomib, lenalidomide and anti-CD20 agents (rituximab, ofatumumab and radioimmunotherapy). Finally, hematopoietic stem cell transplantation (both autologous and allogeneic) remains a useful treatment strategy, although the optimal timing of such approaches requires further clarification.

Original languageEnglish
Pages (from-to)485-495
Number of pages11
JournalExpert Review of Hematology
Issue number4
StatePublished - Aug 2010


  • allogeneic transplantation
  • autologous transplantation
  • bendamustine
  • follicular lymphoma
  • rituximab


Dive into the research topics of 'Follicular lymphoma: Emerging therapeutic strategies'. Together they form a unique fingerprint.

Cite this